GS-6201

**GS-6201** is a selective, high-affinity antagonist of the **A2B adenosine receptor** (A2B AdoR), developed by Gilead Sciences. It potently and selectively blocks the A2B receptor, with more than 500-fold selectivity over the A1, A2A, and A3 adenosine receptor subtypes[1][2]. Mechanistically, GS-6201 inhibits adenosine-mediated proinflammatory signaling and is shown to blunt inflammation, reduce caspase-1 activation, inflammatory cytokines (such as IL-6 and TNF-α), and limit tissue fibrosis and remodeling, particularly after acute myocardial infarction and in models of pulmonary hypertension and lung fibrosis[1][2].

Other names

3-ethyl-1-propyl-8-(1-(3-trifluoromethylbenzyl)-1H-pyrazol-4-yl)-3,7-dihydropurine-2,6-dione